^
    Back
    Association details:
    Biomarker:ER D538G
    Cancer:Breast Cancer
    Drug:fulvestrant (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

    Excerpt:
    ......
    Trial ID:
    NCT04256941
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

    Excerpt:
    ...Y537C, Y537N, Y537S, S463P and D538G....
    Trial ID:
    NCT03202862
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study

    Published date:
    05/26/2022
    Excerpt:
    Transient transfection demonstrated that single mutations D538G, E380Q, F404L and wild-type ESR1 were sensitive to fulvestrant (p < 0.0001, p = 0.0006, p = 0.04 and p = 0.0001), whereas compound mutations D538G_F404L and E380Q_F404L were resistant.
    DOI:
    10.1200/JCO.2022.40.16_suppl.1009
    Trial ID:
    plasmaMATCH
    Test:
    Guardant360® CDx